Sanofi (SNY.US) shares are up 4% today despite an EPS miss and lower-than-expected sales of its blockbuster asthma drug, Dupixent. The positive sentiment is driven by the announcement of a €5 billion share buyback, strong overall sales growth, and plans to expand into high-growth pharmaceuticals.
Dupixent, the main driver of Sanofi’s revenue, fell slightly short of expectations ($3.5 billion) due to fewer selling days and a higher rebate in the U.S. However, the company forecasts higher demand in 2025, as the drug has recently been approved for chronic obstructive pulmonary disease (COPD) treatment.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appOn the other hand, Sanofi’s RSV vaccine, Beyfortus, drove strong Q4 sales of €841 million, exceeding the €679 million analyst estimate. However, the company expects slower growth going forward as it faces potential competition from Merck.
Key Financials (Q4 2024):
- Sales: €10.56 billion (+9.1% YoY), beating the €10.41 billion consensus
- Business EPS: €1.31 (vs. €1.34 estimate, down from €1.54 YoY)
- Business Net Income: €1.64 billion (-15% YoY)
- Operating Income: €2.08 billion (-12% YoY)
- Gross Margin: 74.3% (vs. 76.8% YoY)
- R&D Expenses: €2.26 billion (+24% YoY)
- Free Cash Flow: €2.34 billion
- 2025 Guidance: Mid-to-high single-digit sales growth; low double-digit EPS growth (excluding buyback)
The significant increase in R&D spending reflects Sanofi’s ambition to pivot from consumer health products toward a diversified portfolio of vaccines, rare disease therapies, neurology, and oncology. At the moment, 26 projects are in Phase III trials, and 7 are in the registration process. Paul Hudson has also expressed a particular interest in developing next-generation obesity treatments, currently exploring early-stage candidates. However, the drugmaker remains cautious about joining the already competitive weight-loss drug market.
Sanofi’s stock has seen a strong uptick, especially compared to its competitor Merck. The price has broken above the 38.2 Fibonacci level, setting the stage for a bullish EMA100 crossover (dark purple). RSI is edging into the overbought zone, so stock dynamics might slow until the next major pipeline advancement. Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
